Hospital of Obstetrics and Gynecology, Fudan University, Shanghai, 200080, China.
Reproductive Medicine Center, Xiangya Hospital, Central South University, Changsha, 410000, China.
BMC Womens Health. 2023 Apr 28;23(1):202. doi: 10.1186/s12905-023-02327-x.
Prediction of individual ovarian response to exogenous gonadotropin is a cornerstone for success and safety in all controlled ovarian stimulation (COS) protocols. Providing the best FSH starting dose according to each woman's own characteristics is the key to the success of individualized treatment. The objective of this investigation was to evaluate the potential application of a novel nomogram based on antral follicle counting (AFC), anti-Müllerian hormone (AMH) and body mass index (BMI) as a tool to optimize the follicle-stimulating hormone (FSH) starting dose in women with poor ovarian response in in-vitro fertilization (IVF)/intra-cytoplasmic sperm injection (ICSI) cycles in progestin-primed ovarian stimulation (PPOS). We performed a retrospective analysis involving 130 poor ovarian responders undergoing IVF/ICSI cycles in a PPOS protocol from June 2017 to February 2019 in our reproductive center. The individual FSH starting dose was selected according to patients' clinical history and characteristics. The influence of variables including age, BMI, AMH and AFC on the FSH starting dose was assessed through multiple regression analysis. We used the variables reaching the statistical significance for calculation for the final predictive model. In the univariate analysis, BMI, AMH and AFC were significant (P < 0.05) predictors of FSH starting dose, age was canceled. In the multivariate analysis, BMI, AMH and AFC remained significant (P < 0.05). According to the nomogram, 118 patients (90.77% of 130) would have received a higher FSH starting dose and 12 patients (9.23% of 130) a lower FSH starting dose than practice dose. The application of the nomogram based on three variables easily determined in clinical practice: BMI, AMH and AFC would lead to a more tailored FSH starting dose in women with poor ovarian response.
预测对外源性促性腺激素的个体卵巢反应是所有控制性卵巢刺激(COS)方案成功和安全的基石。根据每个女性自身的特点,提供最佳的促卵泡激素(FSH)起始剂量是个体化治疗成功的关键。本研究旨在评估一种基于窦卵泡计数(AFC)、抗苗勒管激素(AMH)和体重指数(BMI)的新诺莫图在孕激素诱导的卵巢刺激(PPOS)中体外受精(IVF)/卵胞浆内单精子注射(ICSI)周期中卵巢反应不良患者中优化 FSH 起始剂量的潜在应用。我们对 2017 年 6 月至 2019 年 2 月在我们的生殖中心进行 PPOS 方案的 130 例卵巢反应不良患者进行了回顾性分析。根据患者的临床病史和特征选择个体 FSH 起始剂量。通过多元回归分析评估包括年龄、BMI、AMH 和 AFC 在内的变量对 FSH 起始剂量的影响。我们使用达到统计学意义的变量用于最终预测模型的计算。在单因素分析中,BMI、AMH 和 AFC 是 FSH 起始剂量的显著(P<0.05)预测因子,年龄被取消。在多因素分析中,BMI、AMH 和 AFC 仍然具有显著性(P<0.05)。根据诺莫图,118 例患者(130 例的 90.77%)将接受更高的 FSH 起始剂量,12 例患者(130 例的 9.23%)将接受较低的 FSH 起始剂量。在临床实践中,基于三个容易确定的变量(BMI、AMH 和 AFC)的诺莫图的应用将导致卵巢反应不良的妇女更适合的 FSH 起始剂量。